|Designing clinical research|
Lippincott Williams & Wilkins, 2007
|Risk factors for hip fracture in white women|
SR Cummings, MC Nevitt, WS Browner, K Stone, KM Fox, KE Ensrud, ...
New England journal of medicine 332 (12), 767-773, 1995
|Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures|
DM Black, SR Cummings, DB Karpf, JA Cauley, DE Thompson, MC Nevitt, ...
The Lancet 348 (9041), 1535-1541, 1996
|Epidemiology and outcomes of osteoporotic fractures|
SR Cummings, LJ Melton
The Lancet 359 (9319), 1761-1767, 2002
|Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial|
B Ettinger, DM Black, BH Mitlak, RK Knickerbocker, T Nickelsen, ...
Jama 282 (7), 637-645, 1999
|Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis|
DM Black, PD Delmas, R Eastell, IR Reid, S Boonen, JA Cauley, ...
New England Journal of Medicine 356 (18), 1809-1822, 2007
|Denosumab for prevention of fractures in postmenopausal women with osteoporosis|
SR Cummings, JS Martin, MR McClung, ES Siris, R Eastell, IR Reid, ...
New England Journal of Medicine 361 (8), 756-765, 2009
|Hormone therapy to prevent disease and prolong life in postmenopausal women|
D Grady, SM Rubin, DB Petitti, CS Fox, D Black, B Ettinger, VL Ernster, ...
Annals of internal medicine 117 (12), 1016-1037, 1992
|Bone density at various sites for prediction of hip fractures|
SR Cummings, W Browner, DM Black, MC Nevitt, HK Genant, J Cauley, ...
The Lancet 341 (8837), 72-75, 1993
|Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial|
SR Cummings, DM Black, DE Thompson, WB Applegate, ...
Jama 280 (24), 2077-2082, 1998
|Risk factors for recurrent nonsyncopal falls: a prospective study|
MC Nevitt, SR Cummings, S Kidd, D Black
Jama 261 (18), 2663-2668, 1989
|The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial|
SR Cummings, S Eckert, KA Krueger, D Grady, TJ Powles, JA Cauley, ...
Jama 281 (23), 2189-2197, 1999
|Epidemiology of osteoporosis and osteoporotic fractures|
SR Cummings, JL Kelsey, MC Nevitt, KJ O'DOWD
Epidemiologic reviews 7 (1), 178-208, 1985
|Calcium plus vitamin D supplementation and the risk of fractures|
RD Jackson, AZ LaCroix, M Gass, RB Wallace, J Robbins, CE Lewis, ...
New England Journal of Medicine 354 (7), 669-683, 2006
|Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial|
DM Black, AV Schwartz, KE Ensrud, JA Cauley, S Levis, SA Quandt, ...
Jama 296 (24), 2927-2938, 2006
|Vertebral fractures and mortality in older women: a prospective study|
DM Kado, WS Browner, L Palermo, MC Nevitt, HK Genant, SR Cummings
Archives of internal medicine 159 (11), 1215-1220, 1999
|Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial|
DM Black, DE Thompson, DC Bauer, K Ensrud, T Musliner, MC Hochberg, ...
The Journal of Clinical Endocrinology & Metabolism 85 (11), 4118-4124, 2000
|Risk factors for injurious falls: a prospective study|
MC Nevitt, SR Cummings, ES Hudes
Journal of gerontology 46 (5), M164-M170, 1991
|Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial|
JA Cauley, J Robbins, Z Chen, SR Cummings, RD Jackson, AZ LaCroix, ...
Jama 290 (13), 1729-1738, 2003
|The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women|
JA Kanis, A Odén, O Johnell, H Johansson, C De Laet, J Brown, ...
Osteoporosis international 18 (8), 1033-1046, 2007